Search Results - "Raje, N. S."

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma by Richardson, P G, Hofmeister, C C, Raje, N S, Siegel, D S, Lonial, S, Laubach, J, Efebera, Y A, Vesole, D H, Nooka, A K, Rosenblatt, J, Doss, D, Zaki, M H, Bensmaine, A, Herring, J, Li, Y, Watkins, L, Chen, M S, Anderson, K C

“…This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in…”
Get full text

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma by Richardson, P. G., Hofmeister, C. C., Raje, N. S., Siegel, D. S., Lonial, S., Laubach, J., Efebera, Y. A., Vesole, D. H., Nooka, A. K., Rosenblatt, J., Doss, D., Zaki, M. H., Bensmaine, A., Herring, J., Li, Y., Watkins, L., Chen, M. S., Anderson, K. C.

“…Following the publication of this article, the authors noted that the pomalidomide dose for the additional SC cohort in Fig. 1 was incorrectly listed. The…”
Get full text

RADIATION THERAPY AS A BRIDGING AND SALVAGE STRATEGY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA UNDERGOING BCMA‐TARGETED CAR T‐CELL THERAPY by Ababneh, H. S., Yee, A. J., Raje, N. S., Martin, S., Frigault, M. J., Ng, A. K., Patel, C. G.

Get full text

Genetic predisposition for medication-related osteonecrosis of the jaws: a systematic review by Sandro Pereira da Silva, J., Pullano, E., Raje, N.S., Troulis, M.J., August, M.

“…The purpose of this study was to assess whether genetic variation is a predictor for the development of medication-related osteonecrosis of the jaws (MRONJ) in…”
Get full text

A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity by Eda, H, Santo, L, Cirstea, D D, Yee, A J, Scullen, T A, Nemani, N, Mishima, Y, Waterman, P R, Arastu-Kapur, S, Evans, E, Singh, J, Kirk, C J, Westlin, W F, Raje, N S

“…Bruton’s tyrosine kinase (Btk) modulates B-cell development and activation and has an important role in antibody production. Interestingly, Btk may also affect…”
Get full text

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3 by Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez‐Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.‐S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.

Get full text

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA by M Solh, NJ Bahlis, NS Raje, CL Costello, B Dholaria, MY Levy, MH Tomasson, H Dube, MA Damore, HK Lon, C Basu, A Skoura, EM Chan, S Trudel, A Jakubowiak, MP Chu, C Gasparetto, A Dalovisio, M Sebag, AM Lesokhin

“…Objectives: Elranatamab (PF-06863135) is a humanized bispecific monoclonal antibody (IgG2a) that targets BCMA, a member of the tumor necrosis factor receptor…”
Get full text

Low incidence of CNS relapse with cranial radiotherapy and intrathecal methotrexate in acute lymphoblastic leukemia by RAJE, N. S, VAIDYA, S. J, KAPOOR, G, PAI, S. K, NAIR, C. N, KURKURE, P. A, MAGRATH, I. T, ADVANI, S. H

“…To assess the incidence of isolated central nervous system (CNS) relapses in patients of acute lymphoblastic leukemia (ALL) treated with a protocol containing…”
Get full text

Infection analysis in acute lymphoblastic leukemia: a report of 499 consecutive episodes in India by Raje, N S, Rao, S R, Iyer, R S, Kelkar, R S, Pai, S K, Nair, C N, Kurkure, P A, Magrath, I T, Advani, S H

“…The use of empirical antibiotic combinations in the treatment of febrile neutropenic patients has decreased complication-related mortality in cancer patients…”
Get more information

Melanotic neuroectodermal tumor of infancy: report of a case with ganglionic differentiation by Shah, R V, Jambhekar, N A, Rana, D N, Raje, N S, Albuqurque, K V, Mistry, R C, Desai, P B, Advani, S H

“…Melanotic neuroectodermal tumor of infancy (MNTI) is a rare but well-documented lesion of neuroectodermal derivation. Maturation of the neural elements has…”
Get more information

Response with combined modality treatment in childhood rhabdomyosarcoma by Raje, N S, Rao, S R, Vaidya, S J, Shah, R V, Nair, C N, Pai, S K, Kurkure, P A, Pande, S C, Desai, P B, Advani, S H

“…Children diagnosed with rhabdomyosarcoma at the Tata Memorial Hospital during the period January 1986-December 1988 were studied. All were treated with…”
Get more information

Role of the RANK/RANKL Pathway in Multiple Myeloma by Raje, Noopur S, Bhatta, Sumita, Terpos, Evangelos

“…Receptor activator of nuclear factor-kappa B (RANK) and its ligand, RANKL, are expressed in a variety of tissues throughout the body; their primary role is in…”
Get full text

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations by Hyman, David M, Puzanov, Igor, Subbiah, Vivek, Faris, Jason E, Chau, Ian, Blay, Jean-Yves, Wolf, Jürgen, Raje, Noopur S, Diamond, Eli L, Hollebecque, Antoine, Gervais, Radj, Elez-Fernandez, Maria Elena, Italiano, Antoine, Hofheinz, Ralf-Dieter, Hidalgo, Manuel, Chan, Emily, Schuler, Martin, Lasserre, Susan Frances, Makrutzki, Martina, Sirzen, Florin, Veronese, Maria Luisa, Tabernero, Josep, Baselga, José

“…In a basket trial that included patients with a variety of cancers, all of which contained a BRAF V600 mutation, the rate of response to vemurafenib was highly…”
Get full text

Panobinostat and Multiple Myeloma in 2018 by Yee, Andrew J., Raje, Noopur S.

“…FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its…”
Get full text

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial by Yee, Andrew J, MD, Bensinger, William I, MD, Supko, Jeffrey G, PhD, Voorhees, Peter M, MD, Berdeja, Jesus G, MD, Richardson, Paul G, Prof, Libby, Edward N, MD, Wallace, Ellen E, BA, Birrer, Nicole E, BA, Burke, Jill N, MSN, Tamang, David L, PhD, Yang, Min, PhD, Jones, Simon S, PhD, Wheeler, Catherine A, MD, Markelewicz, Robert J, MD, Raje, Noopur S, Dr

“…Summary Background Histone deacetylase (HDAC) inhibitors are an important new class of therapeutics for treating multiple myeloma. Ricolinostat (ACY-1215) is…”
Get full text

Myeloma and Bone Disease by Panaroni, Cristina, Yee, Andrew J., Raje, Noopur S.

“…Purpose of Review Bone disease is a defining characteristic of multiple myeloma (MM) and the major cause of morbidity. It manifests as lytic lesions or…”
Get full text

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma by Rodriguez-Otero, Paula, Usmani, Saad, Cohen, Adam D, van de Donk, Niels W C J, Leleu, Xavier, Gállego Pérez-Larraya, Jaime, Manier, Salomon, Nooka, Ajay K, Mateos, Maria Victoria, Einsele, Hermann, Minnema, Monique, Cavo, Michele, Derman, Benjamin A, Puig, Noemi, Gay, Francesca, Ho, P Joy, Chng, Wee-Joo, Kastritis, Efstathios, Gahrton, Gösta, Weisel, Katja, Nagarajan, Chandramouli, Schjesvold, Fredik, Mikhael, Joseph, Costa, Luciano, Raje, Noopur S, Zamagni, Elena, Hájek, Roman, Weinhold, Niels, Yong, Kwee, Ye, Jing Christine, Sidhana, Surbhi, Merlini, Giampaolo, Martin, Tom, Lin, Yi, Chari, Ajai, Popat, Rakesh, Kaufman, Jonathan L

“…Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall…”
Get full text

Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma by Raje, N. S., Hohl, R. J., Faber, E. A., Richardson, P. G. G., Forero-Torres, A., Schiller, G. J., Cohen, A. D., Carpenter, S. P., Cronier, D., Pashkevich, M., Wooldridge, J., Anderson, K. C.

“…Abstract only…”
Get full text

The effect of selective inhibition of HDAC6 with ACY1215 on bortezomib activity in multiple myeloma (MM) by Santo, L., Hideshima, T., Kung, A. L., Yang, M., Tamang, D., Jarpe, M., van Duzer, J. H., Mazitschek, R., Cirstea, D., Patel, K., Tseng, J., Rodig, S., Pozzi, S., Bradner, J., Anderson, K. C., Jones, S. S., Raje, N. S.

“…Abstract only…”
Get full text

Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study by Anderson, K. C., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D., Knight, R. D., Esseltine, D., Richardson, P. G.

“…Abstract only…”
Get full text